CTOs on the Move

EyePoint Pharmaceuticals

www.eyepointpharma.com

 
EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company`s pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert`s proven intravitreal drug delivery platform has been safely administered to thousands of patients` eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Said Saim
Chief Technology Officer Profile

Funding

EyePoint Pharmaceuticals raised $29M on 10/02/2018
EyePoint Pharmaceuticals raised $15.7M on 01/03/2021
EyePoint Pharmaceuticals raised $45M on 03/09/2022

Similar Companies

Regent Surgical Health

Since 2001, Regent Surgical Health has led the way in developing and managing successful surgery center partnerships. The ASC model is constantly evolving and Regent positions our facility partners to meet these changing market conditions and succeed. Today, a vast majority of our partnerships are Physician/Hospital Joint Ventures. Our experience has led us to develop proprietary ownership models that give both doctors and hospital administrators what they need to ensure long term clinical and financial success. Our success had earned us a reputation as Joint Venture Specialists. Regent has extensive knowledge of the ASC marketplace. We have found successful financial solutions to increase net revenues rather than using out of network strategies, pioneered new procedures such as spine, cardiology, gastric banding, and knee replacements into the ASC environment, and developed both majority and minority hospital partnerships. At Regent, our track record for successful ASC Turnarounds, De Novos, and Joint Ventures is unmatched.

Roxul

Roxul Inc. is a Milton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vesta Healthcare

At Vesta Healthcare, we believe that improving quality of life is possible when we connect technology with clinical expertise, and caregivers and care recipients with the care team.

Fibrocell Science

Making an impact on rare and serious skin and connective tissue diseases Fibrocell Science is at the forefront of the exciting and promising field of personalized biologics. By extracting cells from skin to create localized therapies that are compatible with the unique biology of each patient, personalized biologics bring a transformational approach to drug development. It is Fibrocell’s scientific leadership and legacy in cultivating and harnessing autologous fibroblast cells that fuels its personalized biologics approach. Fibrocell’s proprietary technology uses a person’s own fibroblast cells – with or without genetic modification – to target localized treatment of rare and serious skin and connective tissue diseases.

JustRight Surgical, LLC

JustRight Surgical was founded in order to address a previously unmet need: the ability for pediatric surgeons to safely and effectively perform minimally invasive surgery in pediatric patients from neonate to teenager. Up until 2010, the only devices available for use in pediatric surgery were high-powered adult-sized instruments, which cause access issues and visualization problems during procedures.